These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 32386071)

  • 1. Impact of granulocyte colony-stimulating factor on FOLFIRINOX-induced neutropenia prevention: A population pharmacokinetic/pharmacodynamic approach.
    Macaire P; Paris J; Vincent J; Ghiringhelli F; Bengrine-Lefevre L; Schmitt A
    Br J Clin Pharmacol; 2020 Dec; 86(12):2473-2485. PubMed ID: 32386071
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of G-CSF dosing schedule in patients treated with eribulin: a modeling approach.
    Reda M; Macaire P; Bellio H; Uwer L; Ilie S; Lorgis V; Hennequin A; Ladoire S; Rederstorff E; Fumoleau P; Isambert N; Bonnin N; You B; Freyer G; Desmoulins I; Schmitt A
    Cancer Chemother Pharmacol; 2022 Feb; 89(2):197-208. PubMed ID: 34997290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Prophylactic G-CSF in Patients Receiving FOLFIRINOX: A Preliminary Retrospective Study.
    Terazawa T; Goto M; Miyamoto T; Asaishi K; Shimamoto F; Kuwakado S; Nishitani H; Kii T; Higuchi K
    Intern Med; 2015; 54(23):2969-73. PubMed ID: 26631878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world safety and supportive care use of second-line 5-fluorouracil-based regimens among patients with metastatic pancreatic ductal adenocarcinoma.
    Kim G; Cockrum P; Surinach A; Wang S; Wainberg Z
    Curr Med Res Opin; 2022 Aug; 38(8):1295-1303. PubMed ID: 35354375
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving treatment of chemotherapy-induced neutropenic fever by administration of colony-stimulating factors.
    Mayordomo JI; Rivera F; Díaz-Puente MT; Lianes P; Colomer R; López-Brea M; López E; Paz-Ares L; Hitt R; García-Ribas I
    J Natl Cancer Inst; 1995 Jun; 87(11):803-8. PubMed ID: 7540696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of chemotherapy-induced neutropenia pegylated recombinant human granulocyte colony-stimulating factor: a multi-center randomized controlled phase II clinical study].
    Shi YK; He XH; Yang S; Wang HQ; Jiang ZF; Zhu YZ; Ke XY; Zhang Y; Liu YP; Zhang WJ; Wang Z; Shi QZ; Xie XD; Zhang HL; Wang JJ; Luo DY; Zheng QS; Sun RY
    Zhonghua Yi Xue Za Zhi; 2006 Dec; 86(48):3414-9. PubMed ID: 17313855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A Pancreatic Cancer Patient in Whom Pegfilgrastim Prophylaxis Did Not Prevent Severe Neutropenia Caused by the FOLFIRINOX Regimen].
    Kiba T; Saito Y; Otomo C; Sato M; Meguro T
    Gan To Kagaku Ryoho; 2016 Jul; 43(7):913-5. PubMed ID: 27431641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours.
    Aapro MS; Bohlius J; Cameron DA; Dal Lago L; Donnelly JP; Kearney N; Lyman GH; Pettengell R; Tjan-Heijnen VC; Walewski J; Weber DC; Zielinski C;
    Eur J Cancer; 2011 Jan; 47(1):8-32. PubMed ID: 21095116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial.
    Schwartzberg LS; Bhat G; Peguero J; Agajanian R; Bharadwaj JS; Restrepo A; Hlalah O; Mehmi I; Chawla S; Hasal SJ; Yang Z; Cobb PW
    Oncologist; 2020 Aug; 25(8):e1233-e1241. PubMed ID: 32476162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. G-CSF rescue of FOLFIRINOX-induced neutropenia leads to systemic immune suppression in mice and humans.
    Cardot-Ruffino V; Bollenrucher N; Delius L; Wang SJ; Brais LK; Remland J; Keheler CE; Sullivan KM; Abrams TA; Biller LH; Enzinger PC; McCleary NJ; Patel AK; Rubinson DA; Schlechter B; Slater S; Yurgelun MB; Cleary JM; Perez K; Dougan M; Ng K; Wolpin BM; Singh H; Dougan SK
    J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37344102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Two cases of pancreatic cancer treated with FOLFIRINOX regimen and G-CSF prophylaxis at the standard therapeutic dose].
    Kiba T; Okada Y; Kajiume S; Yamaguchi A
    Gan To Kagaku Ryoho; 2015 May; 42(5):629-32. PubMed ID: 25981661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of once-per-cycle administration pegylated recombinant human granulocyte colony-stimulating factor in chemotherapy-induced neutropenia in a phase I trial].
    Yang S; Shi YK; Liu P; Han XH; He XH; Cai YM; Chen ZM
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Jun; 28(3):339-44. PubMed ID: 16900629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of pegfilgrastim compared to granulocyte colony stimulating factor (G-CSF) supporting a dose-intensive, rapidly cycling anti-metabolite containing chemotherapy regimen (Hyper-CVAD) for lymphoid malignancy.
    Lane SW; Crawford J; Kenealy M; Cull G; Seymour JF; Prince HM; Marlton P; Gill D; Mollee PN
    Leuk Lymphoma; 2006 Sep; 47(9):1813-7. PubMed ID: 17064993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biological and clinical correlates after chemotherapy and granulocyte colony-stimulating factor administration.
    Higa GM; DeVore RF; Auber ML; Lynch JP; Landreth KS
    Pharmacotherapy; 1998; 18(1):1-8. PubMed ID: 9469674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer.
    Crawford J; Ozer H; Stoller R; Johnson D; Lyman G; Tabbara I; Kris M; Grous J; Picozzi V; Rausch G
    N Engl J Med; 1991 Jul; 325(3):164-70. PubMed ID: 1711156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical utility of polyethylene glycol conjugated granulocyte colony-stimulating factor (PEG-G-CSF) for preventing severe neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI plus bevacizumab: a single-center retrospective study.
    Kitagawa Y; Osumi H; Shinozaki E; Ota Y; Nakayama I; Suzuki T; Wakatsuki T; Ogura M; Ooki A; Takahari D; Suenaga M; Chin K; Yamaguchi K
    BMC Cancer; 2020 Apr; 20(1):358. PubMed ID: 32345249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Granulocyte colony-stimulating factor (G-CSF) prevents dose-limiting neutropenia in lymphoma patients receiving standard dose chemotherapy.
    Dotti G; Stella CC; Mangoni L; Cottafavi L; Caramatti C; Almici C; Rizzoli V
    Haematologica; 1995; 80(2):142-5. PubMed ID: 7543069
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, prospective, non-interventional real-world study to assess the effectiveness of mecapegfilgrastim in preventing neutropenia in patients with gastrointestinal cancer.
    Mao C; He Y; Xu N; Yan H; Zhang N; Cheng G; Jiang H; Chen M; Chen Y; Wang X; Gu Y; Shen P; Zhang G; Yan J; Yang Z; Ding L; Han Z; Wang Z; Zhang J; Zheng W; Wang J; Qin S
    Immun Inflamm Dis; 2024 Aug; 12(8):e1348. PubMed ID: 39105572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegfilgrastim and daily granulocyte colony-stimulating factor: patterns of use and neutropenia-related outcomes in cancer patients in Spain--results of the LEARN Study.
    Almenar D; Mayans J; Juan O; Bueno JM; Lopez JI; Frau A; Guinot M; Cerezuela P; Buscalla EG; Gasquet JA; Sanchez J
    Eur J Cancer Care (Engl); 2009 May; 18(3):280-6. PubMed ID: 19076208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.